ICR Acquires Consilium Strategic Communications, Creating Global Leader in Healthcare Communications and Investor Relations
12.9.2023 14:50:00 EEST | Business Wire | Press release
ICR, a leading global strategic communications and advisory firm, today announced it has acquired Consilium Strategic Communications, a leading international strategic healthcare communications and investor relations firm focused on Europe and headquartered in London. The transaction, which follows almost a decade of joint venture collaboration, will combine Consilium with ICR’s US-based healthcare practice, ICR Westwicke, forming a global healthcare strategic and financial communications powerhouse with nearly 200 clients and more than 100 team members across three continents.
Current clients of Consilium will immediately benefit from the full breadth of ICR’s services including: investor relations; capital markets and IPO advisory; investor access; ESG advisory; corporate communications and media relations; crisis and special situations; marketing PR; social media; and branding & design. Consilium will operate under the “ICR Consilium” brand and integrate its teams and activities with ICR’s existing healthcare practice.
Consilium was formed in 2013 by Mary-Jane Elliott, Founder and Managing Partner, along with Amber Fennell, Senior Partner and Co-founder. Over the past 10 years the firm has grown to become the market leader in healthcare strategic communications and IR in Europe. Mary-Jane Elliott will continue to lead the firm from its headquarters in London and both she and Amber Fennell will join the ICR healthcare leadership team, which includes Mark Klausner and Bob East (for Investor Relations), and Terri Clevenger and Michael O’Brien (for Public Relations). The transaction establishes ICR’s first official on-the-ground presence in Europe, broadening its global footprint to now include North America, Asia Pacific and UK/Europe.
Tom Ryan, Founder & CEO of ICR, said: “Consilium has long been recognized as the preeminent healthcare communications and advisory firm across Europe and our years of collaboration have allowed us to learn first-hand what makes them so unique. MJ, Amber and their team have built an incredible business, with a hard-earned reputation for deep sector expertise, highly strategic counsel and outstanding client service. Their business and culture could not align more perfectly with ICR’s and we are thrilled to advance our partnership as a single, unified team.
“We were fortunate to add the Westwicke team to ICR in 2019 and have enjoyed tremendous success since then, growing our healthcare practice nearly three-fold. Combining the Consilium and ICR Westwicke teams allows us to offer truly comprehensive global support to healthcare companies while also extending ICR’s presence into Europe,” Mr. Ryan continued.
Mary-Jane Elliott, Managing Partner at ICR Consilium, said: "Over the past 10 years we have had the great pleasure to build Consilium into Europe's leading independent strategic communications agency for the healthcare sector with the sole purpose of serving our clients globally. I am extremely proud of what we have achieved as a team and thank our clients, colleagues past and present, and fellow advisors for their ongoing trust and support.
"I am excited by our next phase of growth as part of ICR, who are backed by two leading global private equity firms – CDPQ and Investcorp, and what opportunities this offers, particularly in the US, to our clients and colleagues, including offering a broader range of capabilities. We have been joint-venture partners for almost a decade and have a complementary fit in international healthcare PR and IR advisory work. Over the years of working with ICR we have shared many clients and delivered fantastic and seamless benefits, as well as formed strong relationships with the ICR team across the US. Now is the right time to deepen that relationship, which coincides with hopefully the continued re-opening of the capital markets, and we look forward to what we can accomplish together,” Mary-Jane Elliott added.
This transaction creates one of the largest global specialist healthcare communications practices and significantly enhances ICR’s capabilities in Europe, by increasing its practice size in both revenue and headcount and broadening its service offerings. The ICR and Consilium combination will immediately provide existing and new ICR Consilium clients with access to integrated support across ICR’s entire platform of services and the combination creates exciting new growth opportunities for all team members.
Together, ICR and Consilium bring unmatched depth of expertise in healthcare advisory services across IR and strategic communications and the capabilities to support healthcare companies globally across all subsectors including biopharma, medical technology, diagnostics, healthcare services and information technology, and through all stages of growth from early-stage development, to public offerings, to mature public companies. The firm’s full range of critical strategic communication and investor relations services enable the combined team to support healthcare businesses and leaders with strategic expertise for gaining investor support, building and managing reputation, executing and communicating capital raising and other transactions, responding to crises, introducing new products, communicating regulatory developments and more.
Consilium's team of more than 45 PR and IR professionals, including former journalists, sell-side analysts, industry communications experts, and financial PR practitioners combines with ICR Westwicke’s more than 70 team members with similar professional backgrounds in healthcare. Consilium adds to ICR’s existing client base and bolsters the firm’s expertise in strategic healthcare communications and investor relations, with deep industry knowledge and an unrivalled network across the US, UK, continental Europe and Asia.
Amber Fennell, Senior Partner, ICR Consilium, added: “The combination of Consilium with ICR creates an unrivalled transatlantic strategic communications practice providing support across all aspects of healthcare corporate communications and financial transactions. ICR has an excellent brand and reputation and is one of the fastest growing communications agencies in the US. Working together we will be able to provide our combined healthcare clients with even more seamless and integrated access to a breadth of PR and IR advisory services, in London, across Europe and in the US.”
Notes to editors
About ICR
Established in 1998, ICR partners with its clients to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. The firm’s highly-differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to approximately 1,000 clients across more than 20 industry groups. ICR’s healthcare practice operates under the ICR Westwicke brand (www.westwicke.com). Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America, maintaining offices in New York, Norwalk, Boston, Baltimore, San Diego, San Jose and Beijing. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR and LinkedIn.
About ICR Consilium
ICR Consilium is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. ICR Consilium's team, based in Europe and the US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision-makers and executives on critical communications programs, international media management, transactions and healthcare stakeholder challenges. ICR Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.
For more information, please see www.consilium-comms.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912400327/en/
Contact information
For more information:
ICR
Matt Lindberg
Tel: +1(203) 644-7028
Matthew.Linberg@icrinc.com
ICR Consilium
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
info@consilium-comms.com
www.consilium-comms.com
Follow us: @consiliumhc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hydnum Steel Secures 500 MW of Electrical Power, a Key Step Forward in the Construction of Its Clean Steel Plant in Spain27.2.2026 01:00:00 EET | Press release
Hydnum Steel has taken a decisive step towards constructing Spain’s first clean steel plant after being granted access to the electricity grid at the Brazatortas node in the province of Ciudad Real. The company has been granted an electricity capacity of 500 MW, as published in the Official State Gazette, which should be enough to guarantee supply to its electric arc furnace. This concession marks a significant milestone for a pioneering project in the Iberian Peninsula. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225309290/en/ Image recreating the steel plant that Hydnum Steel will build in Puertollano, Spain Hydnum Steel is consolidating its position as a reliable supplier of clean European steel. The fully digitally integrated plant will produce hot-rolled steel coils efficiently and sustainably, with benefits for the environment and the economy. Hydnum Steel will deliver a solution for steel-consuming industries th
1089 Inc. Partners with Price Forbes and Oka-Lloyd's Syndicate 1922 to Launch Market-Defining First: Carbon Asset Insurance Framework for Transportation and Energy Sectors27.2.2026 00:01:00 EET | Press release
1089 Inc., in collaboration with Price Forbes and Oka, The Carbon Insurance Company, announce launch of an insured carbon asset designed to bring institutional safeguards, disciplined financial architecture, and verifiable data integrity to carbon markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226012782/en/ 1089 Inc. is Advancing Carbon™, focused on evolving global carbon markets and decarbonizing the highest-emitting sectors on the planet: Transportation and Energy. The framework provides defined risk coverage for 1089’s CX89 Advanced Fuels Carbon Assets, underwritten by Lloyd’s Syndicate 1922 and placed with the support of Price Forbes and Oka. The program introduces institutional-grade protection designed to prevent performance losses resulting from credit degradation between wrapping and minting. Luke Hanley, Founder and CEO of 1089 Inc., shared the framework’s core thesis: “The future of carbon markets is no
Sun Nuclear QADS 2026 Event Combines Clinical Insight and New Innovations for Advancing Radiation Therapy QA27.2.2026 00:00:00 EET | Press release
Sun Nuclear, a Mirion Medical company, today opened the QA & Dosimetry Symposium (QADS), taking place over the next two days in Rome, Italy. The 15th installment brings together more than 230 clinical physicists and radiation medicine professionals from nearly 40 countries. Participants from diverse clinical environments will earn continuing education credits while sharing practical insights, emerging approaches, and real-world experiences shaping the future of quality and patient safety in cancer care. Building on its legacy as a peer-driven forum with practical applications, QADS 2026 features sessions delivered by 24 speakers spanning: Future Directions in Machine and Patient QA and In-vivo Dosimetry Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) QA Safety and Guideline-driven Tool Selection Emerging Technologies, including Theranostics, AI and Automation Reinforcing its role as a launch point for clinically grounded innovation, QADS 2026 will serve a
Lattice to Highlight Low Power, Edge-Ready Programmable Solutions at embedded world 202626.2.2026 23:00:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for embedded world 2026, where it will demonstrate how its low power, small form factor FPGA innovations help engineers accelerate intelligent, scalable designs from cloud to sensor. At the event, Lattice will participate in expert panel discussions, lead conference sessions, and host an interactive booth experience filled with real-world solutions for the Automotive, Industrial, and Security markets from Lattice and its innovation partners. Who: Lattice Semiconductor What / When: Lattice Booth and Demo Showcase: March 10 – 12, Hall 4, Booth #528 Expert Panel featuring Lattice Chief Strategy and Marketing Officer Esam Elashmawi March 10 at 1:30 p.m. GMT+1, Hall 3, Booth #611 Conference Sessions March 10 at 5 p.m. GMT+1 Safety & Security: “Trusted Resilience Edge – Unified FPGA-TPM for Post-Quantum Cryptography RED & Cyber Resilience Act” March 11 at 10:30 a.m. GMT+1 IoT & Connec
Loomis Sayles Euro Credit Team Celebrates Five-Year Milestones26.2.2026 18:00:00 EET | Press release
Loomis, Sayles & Company, the century-old investment manager with €363.8 billion in assets under management, celebrates the five-year anniversaries of its Loomis Sayles Euro Credit and Loomis Sayles Euro High Yield strategies. The Loomis Sayles Euro Credit Team, led by Co-Heads and Portfolio Managers Rik den Hartog and Pim van Mourik Broekman, manages €3.5 billion in assets across three strategies. Backed by Loomis Sayles’ industry-leading technology infrastructure and focused investment culture, the Euro Credit team seeks to generate consistent excess return versus the benchmark. The team believes this can be accomplished by using an active, conservative alpha investment process that aims to capitalize on inefficiencies in the euro credit market. Loomis Sayles Euro Credit invests primarily in investment grade, euro-denominated corporate bonds while Loomis Sayles Euro High Yield invests primarily in the BB segment of the euro-denominated high yield corporate bond market. The team’s Loo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
